Bora Pharmaceuticals Co Ltd AI Stock Analysis
Bora Pharmaceuticals Co Ltd (6472) AI Stock Analysis
Bora Pharmaceuticals Co Ltd
(TWSE:6472)
Bora Pharmaceuticals earns a moderate score. The strongest support comes from a dramatic rebound in cash generation — free cash flow jumped more than ten-fold to NT$3.31bn — alongside a growing equity base and falling leverage (D/E down to 1.19 from 1.47). Working against this, 2025 saw revenue slip about 4.5% and operating margins compress sharply to 17.3%, pulling return on equity down to 19.4% from 30.6%, while debt of NT$18.2bn remains the principal risk. Technicals add to the caution: the share price sits below all key moving averages with a negative MACD. Valuation is a further headwind, as a 34.6x P/E demands a return to growth that has yet to materialise, though the 2.50% dividend yield offers some compensation. The result is a company with improving financial health but unproven momentum in both earnings and share price.
Bora Pharmaceuticals Co Ltd (6472) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 51.41B
- Dividend Yield
- 2.48%
- Average Volume (3M)
- 840.22K
- Price to Earnings (P/E)
- 32.7
- Beta (1Y)
- 0.16
- Revenue Growth
- -5.57%
- EPS Growth
- -62.77%
- Country
- TW
- Employees
- 2,255
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Bora Pharmaceuticals Co Ltd Business Overview & Revenue Model
Company Description
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including S...
Bora Pharmaceuticals Co Ltd Financial Statement Overview
Summary
A mixed but reasonably solid profile. The income statement (68) shows an impressive multi-year scaling from roughly NT$1.8bn to NT$19bn in revenue, but 2025 was a transition year: revenue fell about 4.5%, net income dropped ~24% to NT$2.98bn, and operating margin compressed to 17.3% from 28.2%, though gross margin held near 40%. The balance sheet (58) is the weakest link — debt of NT$18.2bn against NT$15.4bn equity (D/E 1.19) reflects acquisition-funded growth, although equity grew ~20% and leverage improved from 1.47. Cash flow (76) is the standout, with operating cash flow rebounding to NT$4.24bn from NT$0.98bn and free cash flow surging to NT$3.31bn, covering ~78% of net income. Overall, a profitable business digesting acquisitions, with improving cash generation offset by margin compression and elevated leverage.
Income Statement
68PositiveBalance Sheet
58NeutralCash Flow
76Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.55B | 19.01B | 19.25B | 14.20B | 10.49B | 4.90B |
| Gross Profit | 7.64B | 7.66B | 7.71B | 6.99B | 2.91B | 1.67B |
| EBITDA | 4.08B | 4.23B | 6.46B | 5.86B | 2.27B | 1.29B |
| Net Income | 1.55B | 2.98B | 3.94B | 3.03B | 1.39B | 749.74M |
Balance Sheet | ||||||
| Total Assets | 52.08B | 44.71B | 45.60B | 25.05B | 22.76B | 7.37B |
| Cash, Cash Equivalents and Short-Term Investments | 8.49B | 5.14B | 5.92B | 3.40B | 3.53B | 910.83M |
| Total Debt | 21.82B | 18.23B | 18.98B | 5.01B | 7.60B | 2.23B |
| Total Liabilities | 34.54B | 27.24B | 30.59B | 13.29B | 17.62B | 4.22B |
| Stockholders Equity | 15.12B | 15.38B | 12.87B | 9.08B | 4.53B | 3.15B |
Cash Flow | ||||||
| Free Cash Flow | 1.89B | 3.31B | 293.76M | 3.18B | 1.81B | 873.05M |
| Operating Cash Flow | 3.00B | 4.24B | 980.81M | 4.61B | 2.01B | 1.24B |
| Investing Cash Flow | -3.22B | -3.45B | -10.68B | -2.46B | -4.28B | -225.85M |
| Financing Cash Flow | 3.78B | -1.04B | 12.07B | -2.44B | 4.59B | -741.40M |
Bora Pharmaceuticals Co Ltd Peers Comparison
Overall Rating
- TW:647260Neutral
TW:179557Neutral
TW:694933Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6472 | 60Neutral | TWD 50.12B | 32.71 | ― | 2.48% | -5.57% | -62.77% |
| TW:1795 | 57Neutral | TWD 44.28B | 10.79 | ― | 1.64% | 48.98% | -21.95% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6949 | 33Underperform | TWD 54.47B | -138.20 | ― | ― | 7.81% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6472 | Bora Pharmaceuticals Co Ltd | 403.00 | -209.62 | -34.22% | |
| TW:1795 | Lotus Pharmaceutical Co., Ltd. | 156.00 | -123.55 | -44.20% | |
| TW:6949 | PELL Bio-Med Technology Co Ltd | 44.75 | 25.91 | 137.55% | |
| TW:7799 | Heron Neutron Medical Corp. | 432.00 | -178.00 | -29.18% | |
| TW:7924 | TLC BioSciences Corp | 402.50 | 192.00 | 91.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026